Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
LA JOLLA PHARMACEUTICAL CO (LJPC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/06/2020 |
GN
| La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Progress |
| 07/28/2020 |
GN
| Larry Edwards Appointed President and Chief Executive Officer of La Jolla Pharmaceutical Company |
| 07/28/2020 |
GN
| La Jolla Pharmaceutical Company Announces the Closing of Acquisition of Tetraphase Pharmaceuticals, Inc. |
| 06/24/2020 |
GN
| La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc. |
| 04/13/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Emergency Medical Program in Patients with Septic Shock Due to COVID-19 at CHIREC Delta Hospital, Brussels, Belgium |
| 04/07/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Münster in Germany |
| 04/06/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Royal Surrey County Hospital, Guildford, Surrey, United Kingdom |
| 04/03/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at University Hospital Frankfurt in Germany |
| 04/02/2020 |
GN
| La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19 at Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom |
|
|